Biomedical Research Education & Training
Faculty Member

Dahlman, Kimberly Brown, PhD
Research Assistant Professor of Cancer Biology

Lab Url: http://www.vicc.org/research/shared/translational/

Phone Number: 615-936-6589

Email Address: kimberly.b.dahlman@vanderbilt.edu

Dahlman, Kimberly's picture
Academic history
BS, Lafayette College
PhD, Vanderbilt University
Postdoctoral Fellow, Memorial Sloan-Kettering Cancer Center

Office Address   Mailing Address

722 Preston Research Building

Vanderbilt University 771 Preston Research Building 37232


Research Keywords
Translational Research, SNaPShot, Genotyping, Sequencing, Blood, Tumor, Clinical Research,Chromosome,Genetics,Genome,Genomics,Human Genetics,Malignancy,Mutation

Research Description
The mission of the Innovative Translational Research Shared Resource (ITR) is to advance the translation of basic and clinical research into improved clinical therapies by facilitating clinical discoveries and managing laboratory and clinical data exchange between researchers. The ITR is part of the Personalized Cancer Medicine Initiative that aims to tailor cancer therapies to each cancer patient by characterizing the molecular changes present in an individual's tumor, building a treatment regimen based on those changes, and monitoring the response to those therapies at the molecular level. The laboratory is collaborating with clinical and laboratory investigators at VICC to guide the initiation and completion of pre-clinical research and Phase I and Phase II correlative studies in melanoma, leukemia, lymphoma, head and neck squamous cell carcinoma, graft versus host disease, and breast, pancreas, and lung cancer. The ITR is preparing and housing DNA and RNA from human tumors and blood cells for genetic analysis utilizing Vanderbilt Shared Resources or outside resources. The laboratory is investigating tumor genome alterations by PCR and sequencing, SNaPShot genotyping, whole genome or transcriptome sequencing, microarray, DNA methylation, and gene copy number analysis. In addition, the laboratory is preparing, collecting, and storing whole blood for serum cytokine assays to measure target inhibition, tumor response, and side effects of clinical compounds.

Publications
Dahlman, KB, Parker, JS, Shamu, T, Hieronymus, H, Chapinski, C, Carver, B, Chang, K, Hannon, GJ, Sawyers, CL. Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS One, 7(4), e34414, 2012 PMCID:3324507

Dahlman, KB, Xia, J, Hutchinson, K, Ng, C, Hucks, D, Jia, P, Atefi, M, Su, Z, Branch, S, Lyle, P, Hicks, DJ, Bozon, V, Glaspy, JA, Rosen, N, Solit, DB, Netterville, JL, Vnencak-Jones, CL, Sosman, JA, Ribas, A, Zhao, Z, Pao, W. BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov, 2012

Lovly, CM, Dahlman, KB, Fohn, LE, Su, Z, Dias-Santagata, D, Hicks, DJ, Hucks, D, Berry, E, Terry, C, Duke, M, Su, Y, Sobolik-Delmaire, T, Richmond, A, Kelley, MC, Vnencak-Jones, CL, Iafrate, AJ, Sosman, J, Pao, W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One, 7(4), e35309, 2012 PMCID:3335021

Shi, H, Moriceau, G, Kong, X, Koya, RC, Nazarian, R, Pupo, GM, Bacchiocchi, A, Dahlman, KB, Chmielowski, B, Sosman, JA, Halaban, R, Kefford, RF, Long, GV, Ribas, A, Lo, RS. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov, 2(5), 414-24, 2012

Shi, H, Moriceau, G, Kong, X, Lee, MK, Lee, H, Koya, RC, Ng, C, Chodon, T, Scolyer, RA, Dahlman, KB, Sosman, JA, Kefford, RF, Long, GV, Nelson, SF, Ribas, A, Lo, RS. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun, 3, 724, 2012

Su, Y, Vilgelm, AE, Kelley, MC, Hawkins, O, Liu, Y, Boyd, KL, Kantrow, S, Splittgerber, R, Short, SP, Sobolik-Delmaire, T, Zaja-Milatovic, S, Dahlman, KB, Amiri, KI, Jiang, A, Lu, P, Shyr, Y, Stuart, D, Levy, SE, Sosman, JA, Richmond, A. RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. Clin Cancer Res, 2012

Bivona, TG, Hieronymus, H, Parker, J, Chang, K, Taron, M, Rosell, R, Moonsamy, P, Dahlman, K, Miller, VA, Costa, C, Hannon, G, Sawyers, CL. FAS and NF-I?B signalling modulate dependence of lung cancers on mutant EGFR. Nature, 471(7339), 523-6, 2011

Poulikakos, PI, Persaud, Y, Janakiraman, M, Kong, X, Ng, C, Moriceau, G, Shi, H, Atefi, M, Titz, B, Gabay, MT, Salton, M, Dahlman, KB, Tadi, M, Wargo, JA, Flaherty, KT, Kelley, MC, Misteli, T, Chapman, PB, Sosman, JA, Graeber, TG, Ribas, A, Lo, RS, Rosen, N, Solit, DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 480(7377), 387-90, 2011

Villanueva, J, Vultur, A, Lee, JT, Somasundaram, R, Fukunaga-Kalabis, M, Cipolla, AK, Wubbenhorst, B, Xu, X, Gimotty, PA, Kee, D, Santiago-Walker, AE, Letrero, R, D''Andrea, K, Pushparajan, A, Hayden, JE, Brown, KD, Laquerre, S, McArthur, GA, Sosman, JA, Nathanson, KL, Herlyn, M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 18(6), 683-95, 2010

Brown, KA, Ham, AJ, Clark, CN, Meller, N, Law, BK, Chytil, A, Cheng, N, Pietenpol, JA, Moses, HL. Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1. J Cell Biochem, 105(2), 596-611, 2008 PMCID:2700048

Bonine-Summers, AR, Aakre, ME, Brown, KA, Arteaga, CL, Pietenpol, JA, Moses, HL, Cheng, N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther, 6(4), 561-70, 2007 PMCID:2646635

Brown, KA, Pietenpol, JA, Moses, HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem, 101(1), 9-33, 2007 PMCID:2646635

Barbieri, CE, Tang, LJ, Brown, KA, Pietenpol, JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res, 66(15), 7589-97, 2006 PMCID:2693076

Cheng, N, Bhowmick, NA, Chytil, A, Gorksa, AE, Brown, KA, Muraoka, R, Arteaga, CL, Neilson, EG, Hayward, SW, Moses, HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene, 24(32), 5053-68, 2005 PMCID:2693076

Brown, K, Bhowmick, NA. Linking TGF-beta-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160(ROCK) signaling. Cell Cycle, 3(4), 408-10, 2004 PMCID:400660

Brown, KA, Aakre, ME, Gorska, AE, Price, JO, Eltom, SE, Pietenpol, JA, Moses, HL. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res, 6(3), R215-31, 2004 PMCID:400675

Brown, KA, Roberts, RL, Arteaga, CL, Law, BK. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res, 6(2), R130-9, 2004 PMCID:400660

Xie, L, Law, BK, Chytil, AM, Brown, KA, Aakre, ME, Moses, HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia, 6(5), 603-10, 2004 PMCID:1531665

Bhowmick, NA, Ghiassi, M, Aakre, M, Brown, K, Singh, V, Moses, HL. TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci U S A, 100(26), 15548-53, 2003 PMCID:307605

Yen, CJ, Beamer, BA, Negri, C, Silver, K, Brown, KA, Yarnall, DP, Burns, DK, Roth, J, Shuldiner, AR. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun, 241(2), 270-4, 1997 PMCID:3102744


Postdoctoral Position Available
N/A

Postdoctoral Position Details
N/A

Updated Date
08/13/2012